| Literature DB >> 19245602 |
Abstract
When seriously ill patients for whom existing treatments are inadequate are invited to participate in clinical trials that offer a new treatment, should those persons be considered "vulnerable"? And if so, what additional protections should they be accorded? This article attempts to provide some answers.Entities:
Mesh：
Year: 2009 PMID： 19245602 DOI： 10.1111/j.1748-720X.2009.00350.x
Source DB: PubMed Journal: J Law Med Ethics ISSN： 1073-1105 Impact factor: 1.718